Inclisiran Sodium

CAS 1639324-62-1 1 current recordNucleotide

Who holds supplier records for Inclisiran Sodium? 1 organisation holds a current record for Inclisiran Sodium: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: China (1).

Most records are filed under another form of this substance: Inclisiran (2 current sources). A DMF or CEP is listed under the form it names.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 12 Nov 2026. How we read these records

Cite as: PharmaTek, “Inclisiran Sodium: DMF and CEP holder records”, record as of 12 Nov 2026, pharmatek.co.uk/directory/api/inclisiran-sodium

Reading the evidence

  • One current record

    One organisation holds a current DMF or CEP. A record shows a regulatory filing, not current commercial availability or a qualified source for your product.

  • No company-level GMP certificate matched

    No current EU or UK GMP certificate was matched to these organisations. That is not a negative finding; ask each candidate for its certificate and latest inspection outcome.

Current records (1)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Inclisiran Sodium. Country is the organisation's recorded country, not necessarily the manufacturing site.

  • Yangzhou Aurisco Pharmaceutical Co.,Ltd.
    Active DMF 42095 · latest filing Sept 2025
    China
Need Inclisiran Sodium sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Inclisiran Sodium is a small interfering RNA (siRNA) therapeutic that targets and degrades the mRNA of PCSK9, a protein involved in cholesterol metabolism. It is designed to reduce low-density lipoprotein cholesterol (LDL-C) levels and is used primarily for the treatment of hyperlipidemia.

Therapeutic areas

CardiovascularLipid Metabolism

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Inclisiran Sodium?

1 organisation holds an active US FDA Type II Drug Master File or a CEP for Inclisiran Sodium: Yangzhou Aurisco Pharmaceutical Co.,Ltd. (China). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Inclisiran Sodium Drug Master Files are active?

Yangzhou Aurisco Pharmaceutical Co.,Ltd. (DMF 42095). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

How do I qualify a Inclisiran Sodium supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Inclisiran Sodium?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.